Everything below concerns intranasal delivery. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
稳定性主要由水解与氧化两条路径支配。肽键在中性或弱酸性条件下相对稳定，遇到强碱或长时间高温则明显断裂；甲硫氨酸侧链容易被氧化成亚砜，使主峰前移并拉低实际含量。金属离子、光照和反复冻融会进一步促进降解或聚集。冻干粉在低温避光条件下可存放较长时间，配制后的水溶液通常需要冷藏并尽快用完。
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Analogue of the ACTH(4-10) fragment |
| Amino acid sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Single-letter form MEHFPGP |
| Molecular formula | C37H51N9O10S | Free peptide, nominal mass near 814 Da |
| First registration | 1994, Russia | Nasal formulation for neurological indications |
| Typical purity grade | 95% or higher by HPLC | Research material; higher grades used as reference standards |
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
Material sold for laboratory use varies widely in stated purity and documentation. A certificate of analysis should list the analytical method, the column and detector used, and the observed purity value. Independent verification by an outside laboratory is the practical way to confirm identity when documentation is absent or internally inconsistent. Regulatory status differs by country, and a product legal in one jurisdiction may be unapproved or controlled in another.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
=== Changing rates === The radioactive decay modes of electron capture and internal conversion are known to be slightly sensitive to chemical and environmental effects that change the electronic structure of the atom, which in turn affects the presence of 1s and 2s electrons that participate in the decay process. A small number of nuclides are affected. For example, chemical bonds can affect the rate of electron capture to a small degree (in general, less than 1%) depending on the proximity of electrons to the nucleus. In 7Be, a difference of 0.9% has been observed between half-lives in metallic and insulating environments. This relatively large effect is because beryllium is a small atom whose valence electrons are in 2s atomic orbitals, which are subject to electron capture in 7Be because (like all s atomic orbitals in all atoms) they naturally penetrate into the nucleus. In 1992, Jung et al. of the Darmstadt Heavy-Ion Research group observed an accelerated β− decay of 163Dy66+. Although neutral 163Dy is a stable isotope, the fully ionized 163Dy66+ undergoes β− decay into the K and L shells to 163Ho66+ with a half-life of 47 days. Rhenium-187 is another spectacular example. 187Re normally undergoes beta decay to 187Os with a half-life of 41.6 billion years, but studies using fully ionised 187Re atoms (bare nuclei) have found that this can decrease to only 32.9 years.
== Further reading == Hagedorn, Henry H.; Kunkel, Joseph G. (1979). "Vitellogenin and Vitellin in Insects". Annual Review of Entomology. 24 (4): 475–505. doi:10.1146/annurev.en.24.010179.002355. Wheeler, Diana E.; Kawooya, John K. (1990). "Purification and characterization of honey bee vitellogenin". Archives of Insect Biochemistry and Physiology. 14 (4): 253–267. doi:10.1002/arch.940140405. PMID 2134180. "Vitellogenin Gene Expression in Male Fathead Minnow as an Indicator of Exposure to Endocrine Disrupting Chemicals (EDC) in an Aquatic Environment". EPA.gov. 2006. Amdam, G. V.; Norberg, K.; Omholt, S. W.; Kryger, P.; Lourenço, A. P.; Bitondi, M. M. G.; Simões, Z. L. P. (November 2005). "Higher vitellogenin concentrations in honey bee workers may be an adaptation to life in temperate climates". Insectes Sociaux. 52 (4): 316–319. doi:10.1007/s00040-005-0812-2. S2CID 25197924. Seehuus, S.-C.; Norberg, K.; Gimsa, U.; Krekling, T.; Amdam, G. V. (17 January 2006). "Reproductive protein protects functionally sterile honey bee workers from oxidative stress". Proceedings of the National Academy of Sciences. 103 (4): 962–7. doi:10.1073/pnas.0502681103. PMC 1347965. PMID 16418279. Nelson, C. Mindy; Ihle, Kate E; Fondrk, M. Kim; Page, Robert E; Amdam, Gro V; Chittka, Lars (6 March 2007). "The Gene vitellogenin Has Multiple Coordinating Effects on Social Organization". PLOS Biology. 5 (3): e62. doi:10.1371/journal.pbio.0050062. PMC 1808115. PMID 17341131. Corona, M.; Velarde, R. A.; Remolina, S.; Moran-Lauter, A.; Wang, Y.; Hughes, K. A.; Robinson, G. E. (16 April 2007).
Ideally, the pH of samples should not be modified since it is preferable to test each sample at the original pH level. However, if it is necessary to adjust the pH this should be done by adding either sodium hydroxide solution or hydrochloric acid to the sample. Unlike water samples, soil and sediment samples are not homogeneous. As a result, it is difficult to obtain representative samples from such matrices. Toxic substances are likely to bind to particulate matter, and the extent to which toxic materials bind depends on the composition of the particles. For example, smaller particles such as clay tend to tightly bind to chemicals, acting like ion exchange resins. Microtox tests for sediment and soil differ in the way the matrix is prepared for contact with Allivibrio fischeri. To obtain a representative soil or sediment sample, it is necessary to conduct an elutriate test. Sediment elutriates can be prepared through extraction with either distilled water, saline water, or an organic solvent such as methylene chloride, or hexane. To run an elutriate test a soil sample is mixed with an extractant for a period of time, then allowed to settle and a sample is taken from the extract. If particulate matter is in the sample that was collected, it may be necessary to centrifuge the sample for optimal clarity. Additionally, the pore water of sediments can be collected by centrifugation and tested without extraction.
HA and HA fragment-tumor cell interaction could activate the downstream signaling pathways, promoting cell proliferation, adhesion, migration and invasion, and inducing angiogenesis, lymphangiogenesis, epithelial-mesenchymal transition, stem cell-like property, and chemoradioresistance in digestive cancers.
Dystrophinopathy refers to a spectrum of diseases due to mutations in the DMD gene, which encodes for the dystrophin protein found in muscle. The severe end of the spectrum includes Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and DMD-associated dilated cardiomyopathy. The mild end of the spectrum includes asymptomatic increases in serum creatine kinase and muscle cramps with myoglobinuria. Because dystrophin is located on the X chromosome, dystrophinopathy mainly affects males, whereas females range from being carriers, to having delayed-onset and mild disease, to having severe DMD.
Sources: en.wikipedia.org
Controversy exists as to whether some of these treatments should be acceptable, but one can be more or less forgiven universally: This is the light waxing or oiling applied to most gem turquoise to improve its colour and lustre; if the material is of high quality to begin with, very little of the wax or oil is absorbed and the turquoise therefore does not rely on this impermanent treatment for its beauty. All other factors being equal, untreated turquoise will always command a higher price. Bonded and reconstituted material is worth considerably less. Being a phosphate mineral, turquoise is inherently fragile and sensitive to solvents; perfume and other cosmetics will attack the finish and may alter the colour of turquoise gems, as will skin oils, as will most commercial jewellery cleaning fluids. Prolonged exposure to direct sunlight may also discolour or dehydrate turquoise. Care should therefore be taken when wearing such jewels: cosmetics, including sunscreen and hair spray, should be applied before putting on turquoise jewellery, and they should not be worn to a beach or other sun-bathed environment. After use, turquoise should be gently cleaned with a soft cloth to avoid a buildup of residue, and should be stored in its own container to avoid scratching by harder gems. Turquoise can also be adversely affected if stored in an airtight container.
MRI has a wide range of applications in medical diagnosis and around 50,000 scanners are estimated to be in use worldwide. MRI affects diagnosis and treatment in many specialties although the effect on improved health outcomes is disputed in certain cases. MRI is the investigation of choice in the preoperative staging of rectal and prostate cancer and has a role in the diagnosis, staging, and follow-up of other tumors, as well as for determining areas of tissue for sampling in biobanking.
As early as 1971, Kardashev considered that this observation requires the preparation of a plan of listening and analysis, which will allow the success of the search for extraterrestrial civilizations. Humanity will then be able to solve the "main dilemma", as it was stated by Enrico Fermi. This dilemma is, according to the Soviet astronomer, is certainly connected with our lack of information and knowledge. Kardashev believes that a research project like Ozma is incapable of detecting a Type I civilization (an idea also promoted by Kaplan in 1971), and that SETI should instead focus on searching for intense radio signals that could emanate from active Type II or III civilizations. To prove the effectiveness of this approach, Kardashev therefore turned his attention to two radio sources discovered by the California Institute of Technology, nicknamed CTA-21 and CTA-102. Subsequently, Gennadii Borisovich Sholomitskii then used the Russian astronomical research station to study the data from CTA-102. He found that this radio source is characterized by its variability. Kardashev then considered that this could be an indication of an artificial emission source, albeit of rather short life span.
Hematoxylin and eosin (H&E stain) is one of the most commonly used stains in histology to show the general structure of the tissue. Hematoxylin stains cell nuclei blue; eosin, an acidic dye, stains the cytoplasm and other tissues in different stains of pink. In contrast to H&E, which is used as a general stain, there are many techniques that more selectively stain cells, cellular components, and specific substances. A commonly performed histochemical technique that targets a specific chemical is the Perls' Prussian blue reaction, used to demonstrate iron deposits in diseases like hemochromatosis. The Nissl method for Nissl substance and Golgi's method (and related silver stains) are useful in identifying neurons are other examples of more specific stains.
Sources: en.wikipedia.org
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.
No. The peptide is synthetic, although it is modelled on a fragment of a naturally occurring hormone. ACTH(4-10) is generated when ACTH is cleaved, but the Pro-Gly-Pro extension is not a known endogenous sequence. It is therefore a designed analogue rather than a natural metabolite.
The label reflects reported effects on attention, memory and recovery after neurological injury in regional clinical reports. Those reports are mostly small and have not been widely replicated outside the region. The classification is descriptive and does not imply a single defined mechanism.
电喷雾或基质辅助激光解吸电离质谱是常用手段，测得的质子化离子质荷比可换算为分子量。结果与理论值落在合理误差内，才支持结构一致的判断。